Bimanox

WHAT IS BIMANOX?
Bimanox ophthalmic (eye) drops is used alone or together with other
medicines to treat increased pressure in the eye that is caused by open-angle
glaucoma or a condition called hypertension of the eye (ocular hypertension).
Bimanox is an alpha-adrenergic agonist.
Bimanox is available only with your doctor's prescription.
BIMANOX INDICATIONS
An indication is a term used for the list of condition or symptom or illness for
which the medicine is prescribed or used by the patient. For example,
acetaminophen or paracetamol is used for fever by the patient, or the doctor
prescribes it for a headache or body pains. Now fever, headache and body
pains are the indications of paracetamol. A patient should be aware of the
indications of medications used for common conditions because they can be
taken over the counter in the pharmacy meaning without prescription by the
Physician.
Bimanox Tartrate Ophthalmic Solution is indicated for lowering intraocular
pressure in patients with open-angle glaucoma or ocular hypertension. The
IOP lowering efficacy of Bimanox Tartrate Ophthalmic Solution diminishes
over time in some patients. This loss of effect appears with a variable time of
onset in each patient and should be closely monitored.
HOW SHOULD I USE BIMANOX?
Use Bimanox as directed by your doctor. Check the label on the medicine for
exact dosing instructions.





To use Bimanox in the eye, first, wash your hands. Tilt your head back. Using your
index finger, pull the lower eyelid away from the eye to form a pouch. Drop the
medicine into the pouch and gently close your eyes. Immediately use your finger to
apply pressure to the inside corner of the eye for 1 to 2 minutes. Do not blink.
Remove excess medicine around your eye with a clean, dry tissue, being careful not
to touch your eye. Wash your hands to remove any medicine that may be on them.
To prevent germs from contaminating your medicine, do not touch the applicator tip
to any surface, including the eye. Keep the container tightly closed.
More than 1 eye medicine may be used to lower eye pressure. If you use other
medicines in your eye, wait at least 5 minutes between using Bimanox and your
other eye medicines.
If your medicine comes with a special cap, follow the directions on how to use this
properly.
If Bimanox changes color or becomes cloudy, do not use it. Do not use Bimanox
after the expiration date on the bottle.


Contact your health care provider at once if you feel you have used too much of
Bimanox.
If you miss a dose of Bimanox, use it as soon as possible. If it is almost time for your
next dose, skip the missed dose and go back to your regular dosing schedule. Do
not use 2 doses at once.
Ask your health care provider any questions you may have about how to use
Bimanox.
USES OF BIMANOX IN DETAILS
There are specific as well as general uses of a drug or medicine. A medicine
can be used to prevent a disease, treat a disease over a period or cure a
disease. It can also be used to treat the particular symptom of the disease.
The drug use depends on the form the patient takes it. It may be more useful
in injection form or sometimes in tablet form. The drug can be used for a
single troubling symptom or a life-threatening condition. While some
medications can be stopped after few days, some drugs need to be continued
for prolonged period to get the benefit from it.
Bimanox is used for the treatment of open angle glaucoma or ocular
hypertension (increased pressure inside the eye).
BIMANOX DESCRIPTION
Bimanox is a drug used to treat glaucoma. It acts via decreasing aqueous
humor synthesis. [Wikipedia] A topical gel formulation, marketed under the
name Mirvaso, was FDA approved on August 2013 for the treatment of
rosacea.
BIMANOX DOSAGE
The recommended dose is one drop of ALPHAGAN® P (Bimanox tartrate) in
the affected eye(s) three times daily, approximately 8 hours apart.
ALPHAGAN® P (Bimanox tartrate) ophthalmic solution may be used
concomitantly with other topical ophthalmic drug products to lower intraocular
pressure. If more than one topical ophthalmic product is to be used, the
different products should be instilled at least 5 minutes apart.
How supplied
Dosage Forms And Strengths
Solution containing 1 mg/mL or 1.5 mg/mL Bimanox tartrate.
Storage And Handling
ALPHAGAN® P (Bimanox tartrate) is supplied sterile, in teal opaque plastic
LDPE bottles and tips, with purple high impact polystyrene (HIPS) caps as
follows:
0.1%
5 mL in 10 mL bottle NDC 0023-9321-05
10 mL in 10 mL bottle NDC 0023-9321-10
15 mL in 15 mL bottle NDC 0023-9321-15
0.15%
5 mL in 10 mL bottle NDC 0023-9177-05
10 mL in 10 mL bottle NDC 0023-9177-10
15 mL in 15 mL bottle NDC 0023-9177-15
Storage: Store at 15° - 25°C (59° - 77°F).
Allergan, Inc. Irvine, CA 92612, U.S.A. Revised: 05/2010
BIMANOX INTERACTIONS
Antihypertensives/Cardiac Glycosides Because ALPHAGAN® P (Bimanox
tartrate) may reduce blood pressure, caution in using drugs such as
antihypertensives and/or cardiac glycosides with ALPHAGAN® P (Bimanox
tartrate) is advised.
CNS Depressants
Although specific drug interaction studies have not been conducted with
ALPHAGAN® P (Bimanox tartrate), the possibility of an additive or
potentiating effect with CNS depressants (alcohol, barbiturates, opiates,
sedatives, or anesthetics) should be considered.
Tricyclic Antidepressants
Tricyclic antidepressants have been reported to blunt the hypotensive effect of
systemic clonidine. It is not known whether the concurrent use of these agents
with ALPHAGAN® P (Bimanox tartrate) in humans can lead to resulting
interference with the IOP lowering effect. Caution is advised in patients taking
tricyclic antidepressants which can affect the metabolism and uptake of
circulating amines.
Monoamine Oxidase Inhibitors
Monoamine oxidase (MAO) inhibitors may theoretically interfere with the
metabolism of Bimanox and potentially result in an increased systemic sideeffect such as hypotension. Caution is advised in patients taking MAO
inhibitors which can affect the metabolism and uptake of circulating amines.
BIMANOX SIDE EFFECTS
Clinical Studies Experience
Because clinical studies are conducted under widely varying conditions,
adverse reaction rates observed in the clinical studies of a drug cannot be
directly compared to rates in the clinical studies of another drug and may not
reflect the rates observed in practice.
Adverse reactions occurring in approximately 10-20%of the subjects receiving
Bimanox ophthalmic solution (0.1-0.2%) included: allergic conjunctivitis,
conjunctival hyperemia, and eye pruritus. Adverse reactions occurring in
approximately 5-9% included: burning sensation, conjunctival folliculosis,
hypertension, ocular allergic reaction, oral dryness, and visual disturbance.
Adverse reactions occurring in approximately 1-4% of the subjects receiving
Bimanox ophthalmic solution (0.1-0.2%) included: abnormal taste, allergic
reaction, asthenia, blepharitis, blepharoconjunctivitis, blurred vision,
bronchitis, cataract, conjunctival edema, conjunctival hemorrhage,
conjunctivitis, cough, dizziness, dyspepsia, dyspnea, epiphora, eye discharge,
eye dryness, eye irritation, eye pain, eyelid edema, eyelid erythema, fatigue,
flu syndrome, follicular conjunctivitis, foreign body sensation, gastrointestinal
disorder, headache, hypercholesterolemia, hypotension, infection (primarily
colds and respiratory infections), insomnia, keratitis, lid disorder, pharyngitis,
photophobia, rash, rhinitis, sinus infection, sinusitis, somnolence, stinging,
superficial punctate keratopathy, tearing, visual field defect, vitreous
detachment, vitreous disorder, vitreous floaters, and worsened visual acuity.
The following reactions were reported in less than 1% of subjects: corneal
erosion, hordeolum, nasal dryness, and taste perversion.
Postmarketing Experience
The following reactions have been identified during postmarketing use of
Bimanox tartrate ophthalmic solutions in clinical practice. Because they are
reported voluntarily from a population of unknown size, estimates of frequency
cannot be made. The reactions, which have been chosen for inclusion due to
either their seriousness, frequency of reporting, possible causal connection to
Bimanox tartrate ophthalmic solutions, or a combination of these factors,
include: bradycardia, depression, hypersensitivity, iritis, keratoconjunctivitis
sicca, miosis, nausea, skin reactions (including erythema, eyelid pruritus,
rash, and vasodilation), syncope, and tachycardia. Apnea, bradycardia, coma,
hypotension, hypothermia, hypotonia, lethargy, pallor, respiratory depression,
and somnolence have been reported in infants receiving Bimanox tartrate
ophthalmic solutions.
BIMANOX CONTRAINDICATIONS
Do not use Bimanox ophthalmic if you have used an MAO inhibitor such as
isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline
(Eldepryl, Emsam), or tranylcypromine (Parnate) within the past 14 days.
Before using Bimanox ophthalmic, tell your doctor if you have kidney or liver
disease, heart disease, high blood pressure, circulation problems such as
Raynaud's or Buerger's disease, or a history of fainting or low blood pressure.
Do not use this medication while you are wearing contact lenses. This
medication may contain a preservative that can be absorbed by soft contact
lenses. Wait at least 15 minutes after using Bimanox before putting your
contact lenses in.
Do not allow the dropper tip to touch any surface, including the eyes or hands.
If the dropper becomes contaminated it could cause an infection in your eye,
which can lead to vision loss or serious damage to the eye.
https://www.ndrugs.com/?s=bimanox#doctor_indications